Search ICUI
ICU MEDICAL INC/DE
Nasdaq · CIK 883984
Last close159.38
Daily change+2.20 (1.40%)
10 Years gain+26.19%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
ICUI · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
46.4Momentum
63.9Acceleration
60.6Confidence
83.0Annual Revenue19
Quarterly Revenue76
Annual CFO19
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth7.5 / 25
Quality18.6 / 25
Capital Efficiency4.2 / 20
Balance Sheet8.0 / 15
Shareholder Economics5.8 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 4.9551 percentage points.
Operating leverageOperating margin improved by 2.7821 percentage points.
ROIC expansionROIC improved by 1.1083 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Warnings
Low interest coverage · HIGHInterest coverage is 1.0608x.
Key Metrics
Revenue Growth TTM-8.03%OK
Revenue CAGR 3Y-0.72%OK
Gross Margin39.22%OK
Operating Margin3.55%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC1.51%OK
Incremental Operating Margin 3Y11.42%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y2.06%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $2.23B | $822.04M | $42.83M | $179.85M | $91.80M | 36.84% | 1.92% | 4.11% | 1.07% | 24.9M |
| 2025 FY Dec 31, 2024 | $2.38B | $824.78M | $42.96M | $204.03M | $124.66M | 34.62% | 1.8% | 5.23% | 1.01% | 24.39M |
| 2025 FY Dec 31, 2023 | $2.26B | $739.87M | $22.83M | $166.20M | $82.31M | 32.75% | 1.01% | 3.64% | 0.51% | 24.09M |
| 2024 FY Dec 31, 2022 | $2.28B | $697.76M | -$42.90M | -$62.13M | -$152.44M | 30.6% | -1.88% | -6.69% | -1.48% | 23.87M |
| 2023 FY Dec 31, 2021 | $1.32B | $491.49M | $123.25M | $267.54M | $199.00M | 37.34% | 9.36% | 15.12% | 9.1% | 21.78M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $2.17B | sum latest 4 fiscal quarters Revenue | OK | 0000883984-26-000041, 0000883984-25-000035 |
| Revenue Growth TTM | -8.03% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000883984-26-000041, 0000883984-25-000035 |
| Revenue CAGR 3Y | -0.72% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0000883984-26-000008 |
| Revenue CAGR 5Y | 11.91% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0000883984-26-000008 |
| Gross Profit CAGR 3Y | 5.62% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0000883984-26-000008 |
| Operating Income Growth | 324.05% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0000883984-26-000041, 0000883984-25-000035 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 39.22% | Gross Profit / Revenue | OK | 0000883984-26-000041, 0000883984-25-000035 |
| Operating Margin | 3.55% | Operating Income / Revenue | OK | 0000883984-26-000041, 0000883984-25-000035 |
| ROIC | 1.51% | NOPAT / Average Invested Capital | OK | 0000883984-26-000041, 0000883984-25-000035 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0000883984-26-000041 |
| Interest Coverage | 1.06x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 2.43x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.24x | (Cash + Short-term Investments) / Total Debt | OK | 0000883984-26-000041 |